Publicaciones científicas
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Paula Rodriguez-Otero 1 , Sikander Ailawadhi 2 , Bertrand Arnulf 3 , Krina Patel 4 , Michele Cavo 5 , Ajay K Nooka 6 , Salomon Manier 7 , Natalie Callander 8 , Luciano J Costa 9 , Ravi Vij 10 , Nizar J Bahlis 11 , Philippe Moreau 12 , Scott R Solomon 13 , Michel Delforge 14 , Jesus Berdeja 15 , Anna Truppel-Hartmann 16 , Zhihong Yang 17 , Linda Favre-Kontula 17 , Fan Wu 17 , Julia Piasecki 17 , Mark Cook 17 18 , Sergio Giralt 19
What is this summary about?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed).
How was this study conducted?: In the KarMMa-3 study, people with relapsed or refractory multiple myeloma received either a one-time infusion of a new treatment, named ide-cel, or one of the standard of care regimens currently available for patients with this cancer. People were treated with the standard of care regimens in weekly or monthly cycles until the cancer got worse, there were unacceptable side effects, or the person withdrew from the study.
What were the results?: The results of this study showed that people receiving the one-time infusion of ide-cel lived longer without the cancer getting worse and had a greater reduction in cancer cells than patients receiving the standard of care regimen. A higher percentage of patients receiving ide-cel responded to treatment than patients receiving the standard of care regimen, and the response to treatment was better with idecel. These results show that ide-cel is a promising treatment for this challenging disease. Clinical Trial Registration: NCT03651128 (KarMMa-3 study).
CITA DEL ARTÍCULO Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954
Nuestros autores
